Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Liabilities (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Total Liabilities data on record, last reported at $889.5 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 8.8% year-over-year to $889.5 million; the TTM value through Sep 2025 reached $889.5 million, up 8.8%, while the annual FY2024 figure was $845.2 million, 3.24% down from the prior year.
  • Total Liabilities reached $889.5 million in Q3 2025 per AMPH's latest filing, up from $857.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $949.5 million in Q3 2023 and bottomed at $194.8 million in Q1 2021.
  • Average Total Liabilities over 5 years is $554.7 million, with a median of $778.2 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: skyrocketed 328.61% in 2023, then decreased 13.9% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $226.0 million in 2021, then decreased by 5.61% to $213.3 million in 2022, then surged by 309.46% to $873.5 million in 2023, then fell by 3.24% to $845.2 million in 2024, then increased by 5.24% to $889.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $889.5 million in Q3 2025, $857.9 million in Q2 2025, and $875.0 million in Q1 2025.